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Steroidogenic factor 1 (SF1, NR5A1) is a nuclear receptor that regulates multiple genes involved in adrenal and
gonadal development, steroidogenesis, and the reproductive axis. Human mutations in SF1 were initially found
in two 46,XY female patients with severe gonadal dysgenesis and primary adrenal failure. However, more recent
case reports have suggested that heterozygous mutations in SF1 may also be found in patients with 46,XY partial
gonadal dysgenesis and underandrogenization but normal adrenal function. We have analyzed the gene encoding
SF1 (NR5A1) in a cohort of 27 patients with 46,XY disorders of sex development (DSD) from the German
network of DSD. Heterozygous SF1 mutations were found in 5 out of 27 (18.5%) of cases. Four patients with
SF1 mutations presented with the similar phenotype of mild gonadal dysgenesis, severe underandrogenization,
and absent Mu ¨llerian structures. Of these, two patients harbored missense mutations within the DNA-binding
region of SF1 (p.C33S, p.R84H), one patient had a nonsense mutation (p.Y138X) and one patient had a
frameshift mutation (c.1277dupT) predicted to disrupt RNA stability or protein function. One additional
patient ([c.424_427dupCCCA]1[p.G146A]) displayed a more marked phenotype of severe gonadal
dysgenesis, normal female external genitalia, and Mu ¨llerian structures. Functional studies of the missense
mutants (p.C33S, p.R84H) and of one nonsense mutant (p.Y138X) revealed impaired transcriptional activation
of SF1-responsive target genes. To date, adrenal insufficiency has not occurred in any of the patients. Thus, SF1
mutations are a relatively frequent cause of 46,XY DSD in humans. Hum Mutat 29(1), 59–64, 2008. r r 2007
Wiley-Liss, Inc.
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INTRODUCTION
Steroidogenic factor-1 (SF1/Ad4BP , NR5A1; MIM] 184757) is
a nuclear receptor that was first identified following the search for
a common regulator of the cytochrome P450 steroid hydroxylase
family of enzymes [Lala et al., 1992]. Subsequent studies have
revealed that SF1 regulates a great number of genes involved in
gonadal and adrenal development, reproduction and steroidogen-
esis [Parker et al., 2002].
SF1 is believed to bind to the response elements of target genes as
a monomer. Critical regions of SF1 involved in transcriptional
regulation include a two zinc finger DNA-binding domain (DBD),
an ‘‘A’’ box region found in monomeric nuclear receptors, a hinge
region, and a helical ligand-binding domain (LBD) region containing
an activation function-2 (AF-2) domain [Parker and Schimmer,
1997]. Crystalization of the LBD of SF1 has revealed that
phospholipids may act as ligands for SF1 [Krylova et al., 2005].
SF1 is essential for gonadal and adrenal differentiation in
mammals. In mice and humans, SF1 is expressed very early in the
urogenital ridge and continues to be highly expressed in the
developing adrenal, gonad, ventromedial hypothalamus, and
pituitary [Hatano et al., 1994; Ingraham et al., 1994; Hanley
et al., 1999]. Targeted disruption of Sf1 (Ftzf1) in mice results in
gonadal and adrenal agenesis, persistence of Mu ¨llerian structures
and abnormalities of the hypothalamus and pituitary gonadotropes
[Luo et al., 1994; Majdic et al., 2002]. Heterozygous animals have
a milder phenotype including an impaired adrenal stress response
and reduced testicular size [Bland et al., 2000].
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r r 2007 WILEY-LISS, INC.In humans, SF1 mutations were first described in patients with
46,XY disorders of sex development (DSD), Mu ¨llerian structures,
and primary adrenal failure (MIM] 184757) [Achermann et al.,
1999, 2002]. The first of these mutations (p.G35E) was a de novo
heterozygous change affecting a critical amino acid in the ‘‘P’’ box
region of the first zinc-finger of the DNA binding domain that
severely affects SF1 function [Achermann et al., 1999; Ito et al.,
2000]. The second mutation was a recessively-inherited homo-
zygous change (p.R92Q) affecting the ‘‘A’’ box of SF1 and causing
partial loss of function [Achermann et al., 2002]. A heterozygous
SF1 mutation has also been reported in a 46,XX female with
primary adrenal failure and apparently normal ovarian develop-
ment [Biason-Lauber and Schoenle, 2000].
Recently, heterozygous SF1 mutations have been described in
seven 46,XY patients with ambiguous genitalia, gonadal dysgen-
esis, but no adrenal insufficiency [Correa et al., 2004; Mallet et al.,
2004; Hasegawa et al., 2004; Lin et al., 2007]. The potential
dosage-dependent actions of SF1 suggest that these heterozygous
SF1 changes might lead to a partial phenotype of 46,XY DSD with
normal adrenal function. Here, we report five novel SF1 mutations
identified in a cohort of 27 patients with severe underandrogen-
ization and variable degrees of gonadal dysgenesis. These results
suggest that heterozygous SF1 changes are a relatively frequent
finding in patients with 46,XY gonadal dysgenesis/DSD.
MATERIALSANDMETHODS
Patients
The cohort studied consisted of 27 46,XY patients from the
‘‘German Network of Disorders of Sex Development.’’ The
patients had presented with phenotypes ranging from ambiguous
genitalia to normal female genitalia and had been diagnosed with
variable degrees of gonadal dysgenesis. Mu ¨llerian structures were
reported in 17 patients. Adrenal insufficiency was not present in
any of them. Dysmorphic or systemic features (e.g., kidney, heart,
limbs) were absent. Informed consent for the genetic studies was
obtained from all parents or patients according to institutional
guidelines.
MolecularAnalysis of NR5A1
Genomic DNA was extracted from peripheral blood leukocytes
and exons 2–7 of the gene encoding SF1 (NR5A1) were PCR-
amplified (primer sequences available on request). PCR products
were purified using exonuclease 1 and shrimp alkaline phosphatase
(New England Biolabs, Cambridge, UK; USB, Cleveland, OH) and
sequenced using a V3 kit and 3130x analyzer (Applied Biosystems,
Foster City, CA). DNA mutation numbering is based on GenBank
reference DNA sequence NM_004959.3, with the A of the ATG
initiation codon designated 11 (www.hgvs.org/mutnomen).
Electromobility ShiftAssays
Wild-type (WT) and mutant SF1 proteins were in-vitro
translated from the pCMX expression vector using the TNT
reticulocyte system (Promega, Southampton, UK). Synthetic
oligonucleotide probes corresponding to the 30 SF1 binding site
on the Cyp11a minimal promoter were labeled with [
32P]dCTP by
Klenow polymerase and electromobility shift assays were per-
formed as described previously [Ito et al., 2000].
Studies of SF1Expression and Nuclear Localization
Mutant green fluorescent protein (GFP)-SF1 constructs were
generated by site-directed mutagenesis in a pAcGFP-C1 vector
(Clontech, Oxford, UK) to produce mutant fusion proteins with a
GFP tag at the amino-terminus of SF1. Studies of protein
expression and cellular localization were performed by transfecting
WT and mutant pAcGFP-C1SF1 expression vectors (0.8mg) into
tsa 201 human embryonic kidney cells. After 24hr, cells were fixed
and nuclear counterstaining performed with Vectashield contain-
ing DAPI (Vector Laboratories, Peterborough, UK).
Transient Gene Expression Assays
Expression vectors containing the p.C33S and p.R84H missense
mutants and p.Y138X nonsense mutant were generated by site-
directed mutagenesis (QuikChange, Stratagene, Amsterdam, The
Netherlands) using WT pCMXSF1 as a template. Transient
transfection studies were performed in 96-well plates using
Lipofectamine 2000 (Invitrogen, Paisley, UK) and a Dual-
Luciferase reporter assay system (Promega). Initial studies were
performed in tsa 201 cells by transfecting empty, WT, or mutant
SF1 expression vectors (2ng/well) (p.G35E, p.C33S, p.R84H,
p.Y138X) with SF1-responsive minimal promoters linked to
luciferase (100ng/well) (data shown for Cyp11a). In addition,
synergistic activation of the LHb promoter by SF1 and Egr1 (2ng/
well) was studied in tsa 201 cells, as described previously
[Lin et al., 2007]. Finally, WT or mutant SF1 vectors (10ng/
well) were cotransfected with Cyp11a and MIS reporters into TM3
(mouse Leydig) and TM4 (mouse Sertoli) cells, respectively. Cells
were lysed for 24hr following transfection and assayed for
luciferase activity (FLUOstar Optima; BMG Labtech, Aylesbury,
UK), with standardization for Renilla coexpression.
Studies of Potential Dominant Negative Interactions
Studies of WT/mutant interactions were performed by trans-
fecting increasing amounts of pCMXWTor mutant SF1 expression
vector (0, 1, 2, 5, 10ng) with either 1ng empty vector or 1ng WT
SF1 and Cyp11a reporter (100ng) in tsa 201 cells. Luciferase
assays were performed as described above.
RESULTS
Cohort Analysis
SF1 mutations were found in 5 out of 27 (18.5%) patients
studied. An overview of these changes and clinical phenotypes is
provided in Table 1 and Figure 1.
Case Histories
Patients 1–4 were diagnosed with ambiguous genitalia at birth.
All these individuals presented with a similar genital phenotype
consisting of phallic hypoplasia/clitoromegaly, fusion of the
labioscrotal folds, a single perineal opening representing a
urogenital sinus, and palpable inguinal gonads. The karyotype
was found to be 46,XY in each case, but Mu ¨llerian structures
(uterus, upper vagina) were absent. Gonadectomy—performed
before the age of 2 years—revealed bilateral testes with Wolffian
structures (epididymides, vasa deferentia). Endocrine evaluation
at diagnosis showed low testosterone levels before and after human
chorionic-gonadotropin (hCG) stimulation in Patients 1, 2 and 4,
and low basal testosterone in Patient 3 (Table 1). In all patients,
female gender assignment was made because of the significant
undervirilization and clitoroplasty were undertaken following
discussion and with parental consent.
Patient 5 presented as a young adult with primary amenorrhea.
She had normal female external genitalia. Gonadotropins (follicle-
stimulating hormone [FSH] 111.9U/l; luteinizing hormone [LH]
25.8U/l) were elevated, karyotype was found to be 46,XY, and
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ultrasound (Table 1).
Basal cortisol and dehydroepiandrosterone sulfate (DHEAS)
were within normal ranges in Patients 1–4 and no symptoms or
signs of adrenal insufficiency have emerged during follow-up
(Table 1). A synacthen stimulation test performed at 17 years of
age in Patient 2 showed a very good cortisol response.
SF1 (NR5A1) Mutations
An overview of the SF1 (NR5A1) mutations detected is shown
in Table 1 and Figure 1. Patients 1 and 2 harbor heterozygous
missense mutations in SF1 (Patient 1: c.98G4C, p.C33S; Patient
2: c.251G4A, p.R84H), whereas Patient 3 has a heterozygous
nonsense mutation (c.414C4A, p.Y138X). Patient 4 is hetero-
zygous for a single nucleotide duplication (c.1277dupT), which is
predicted to result in a frameshift and disruption of the ligand
binding domain of SF1. Her mother also carries this heterozygous
change. Patient 5 has a 4 base pair duplication (c.424_427dupCC-
CA) in exon 4 in one allele, which is predicted to result in
a frameshift and premature stop codon after seven amino acids.
A c.437G4C polymorphism (p.G146A) was present on the
second allele, which was confirmed by subcloning the patient’s
DNA. Analysis of DNA from 100 healthy control subjects did not
detect any of these key novel changes by restriction analysis (data
not shown). The p.G146A change is a recognized nonsynonymous
polymorphism in SF1 (rs1110061).
Electromobility ShiftAssays
Studies of the 30 Cyp11a promoter showed absent binding for
the p.C33S mutant consistent with its position within the ‘‘P’’ box
TABLE 1. Phenotypes,Genotypes, andHormonal Data of the FivePatients
Patient
Age
(years)
External
genitalia Uterus
Epididymis
andvas
deferens Gonadal histology
Testosterone
levels at diagnosis
Gender
assignment
Adrenal
investigations
(at current age) Mutation Parents
1 4 Clitoromegaly,
urogenital
sinus,
inguinal
gonads
No Yes Bilateral testes,
Sertoli rich,
few spermatogonia
and Leydig
cells
hCG stimulation at birth:
testosterone
o0.08-0.07 ng/ml
~ Cortisol 3.6 mg/dl
DHEAS 50ng/ml
ACTH 25 pg/ml
p.C33S
(c.98G4C,
exon2)
Mother: normal;
father: normal
2 17 Clitoromegaly,
urogenital
sinus,
inguinal
gonads
No Yes Bilateral testes hCG stimulation at 2 years:
testosterone
o0.01-2.5ng/ml
~ Cortisol
7.4 to 24.9 mg/dl
a
DHEAS 1230 ng/ml
ACTH 14 pg/ml
p.R84H
(c.251G4A,
exon 4)
Mother: normal;
father: NA
3 10 Clitoromegaly,
urogenital
sinus,
inguinal
gonads
No Yes Bilateral testes,
Sertoli cells
only
At birth:
testosterone 0.25ng/ml
~ Cortisol 7.2 mg/dl
DHEAS 891ng/ml
p.Y138X
(c.414C4A,
exon 4)
Mother: normal;
father: NA
4 8 Clitoromegaly,
urogenital
sinus,
inguinal
gonads
No Yes Bilateral testes hCG stimulation at birth:
testosterone
0.86-0.86 ng/ml
~ Cortisol 6.7 mg/dl
DHEAS 548ng/ml
c.1277dupT
(exon 7)
Mother:
c.1277dupT;
father: NA
52 2 N o r m a l
female,
no palpable
gonads
Yes Not known Bilateral streak
gonads
At 22 years:
LH 25.8U/l
FSH111.9U/l
estradiol 7pg/ml
testosterone 0.2ng/ml
~ NA c.424_427
dupCCCA 1
p.G146A
polymorphism
(c.437G4C)
(bothexon 4)
Mother: NA;
father: NA
Normal ranges: basal cortisol, 3^15mg/dl (o0.5^10 years); DHEAS, o50^352ng/ml (0.5^7 years), 75^1,312ng/ml (7^10 years), 150^4,400ng/ml (410 years); ACTH,
9^50pg/ml. Conversion to SI units: testosterone ng/ml 3.47 for nmol/l; cortisol mg/dl 27.6 for nmol/l; DHEAS ng/ml 2.56 for nmol/l; ACTH pg/ml 0.22 for pmol/l.
DNA mutationnumberingisbasedontheGenBankreferenceDNA sequenceNM_004959.3 usingcurrentguidelines (www.hgvs.org/mutnomen) andwith theAof theATG initia-
tioncodon designated 11.
aPeakcortisol followingsynacthenstimulation.‘‘At birth’’refers to the ¢rst weekof life.
ACTH, adrenocorticotropin; NA, not analyzed.
Y138X R84H C33S c.424_427dupCCCA+G146A c.1277_1278insT
Zinc
fingers
A
box Ligand-like BD AF-2
461 1
L437Q c.1058_1065del
AGCTGGTG
R255L R92Q G35E c.18delC
V15M
C16X
C33S R84H Y138X c.424_427dupCCCA+G146A c.1277dupT
M78I G91S
FIGURE 1. StructureofSF1includingthepositionofSF1mutationsin 46,XYpatientswithdisorders ofsexdevelopment. p.G35E and
p.R92Q are the ¢rst mutations described in SF1 in 46,XY individuals with gonadal dysgenesis and adrenal failure. p.R255L was
foundinanormal46,XXfemalewithadrenalfailure.Theothermutationshavebeenidenti¢edinindividualswith 46,XYDSDwithout
adrenal insu⁄ciency.The ¢ve novel mutations reported here are boxed. DNA RefSeqNM_004959.3.
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protein both showed reduced binding (Fig. 2A).
SF1Expression and Cellular Localization
GFP-tagged WT SF1 showed strong nuclear localization with
nucleolar exclusion. A similar pattern was seen with the p.R84H
mutant vector. The p.C33S construct showed marked subnuclear
focal aggregation in many cells, whereas the p.Y138X nonsense
mutant appeared to be located in a diffuse pattern throughout the
nucleus (Fig. 2B).
Functional Studies ofSF1Activity
All mutants studied (p.C33S, p.R84H, p.Y138X) showed
markedly impaired transcriptional activity (Fig. 3A–D). Cotrans-
fection of mutant with WT SF1 did not show a dominant negative
effect even when 10:1 ratios of mutant:WT vector were
transfected (Fig. 3E). The p.G146A polymorphism in SF1 has
been shown previously to be associated with approximately 80%
WTactivity [WuQiang et al., 2003].
DISCUSSION
Here, we present five novel heterozygous SF1 mutations in a
cohort of 27 46,XY patients (18.5%) with severe underandrogen-
ization but without adrenal insufficiency. These findings substan-
tially increase the number of SF1 (NR5A1) mutations reported in
humans, and show that mutations in SF1 can be found in patients
with a range of phenotypic features (Table 2).
Within our series, four patients (heterozygous p.C33S, p.R84H,
p.Y138X, and c.1277dupT) presented with a similar phenotype
consisting of severe underandrogenization of the external genitalia,
bilateral testes, and Wolffian structures, but absence of Mu ¨llerian
structures (uterus, fallopian tubes). These findings suggest that
androgen biosynthesis and action were compromised during early
fetal development (9–16 weeks), but that sufficient secretion of
anti-Mu ¨llerian hormone (AMH) occurred from Sertoli cells to
allow regression of Mu ¨llerian structures during this critical
developmental period. The presence of well-formed Wolffian
structures in Patients 1–4 is unusual given the degree
of underandrogenization observed. Whether the development
of Wolffian structures with relatively impaired androgenization of
the external genitalia will be a feature that distinguishes
SF1 mutations from other diagnoses, such as partial gonadal
dysgenesis or partial androgen insensitivity, remains to be seen.
The identification of naturally-occurring missense mutations in
SF1 is also helping to reveal important functional domains for
nuclear receptor action. The amino acids of the missense
mutations (p.C33S, p.R84H) are highly conserved in different
species. The mutated cysteine (p.C33S) plays a central role in
formation of the first zinc finger of the DNA binding domain of
SF1 (Fig. 1). The C33S change results in impaired DNA binding
to SF1 response elements (Fig. 2A), a complete loss of
transcriptional activation without dominant negative activity
(Fig. 3A–E) and abnormal clustering in sub-nuclear aggregations
(Fig. 2B). These foci likely represent promyelocytic leukemia
(PML) or nuclear domain 10 (ND10) bodies, and have been
reported previously with several nuclear receptor mutations
associated with human disease [Baumann et al., 2001; Vottero
et al., 2002; Black et al., 2004]. The arginine at position 84 lies
between the zinc-fingers and ‘‘A’’-box of SF1 in the carboxyl-
terminal DNA-binding region (Fig. 1). This change also disrupts
DNA binding and transcriptional activation, with little effect on
cellular localization. Finally, the nonsense mutation (p.Y138X)
results in a truncated protein with loss of the LBD, and the
frameshift mutation resulting from the duplication c.1277dupT is
predicted to lead to abnormal protein sequence. However, it is
feasible that RNA containing the Y138X change is subject to
nonsense-mediated decay.
Compared to the first four individuals, Patient 5 has a more
severe phenotype, as she has normal female external genitalia and
presented only in adolescence with absent breast development and
primary amenorrhea. A uterus and streak gonads were found. The
mutation c.424_427dupCCCA results in a frameshift and premature
stop codon after seven amino acids. In addition to this heterozygous
frameshift change, Patient 5 also harbors a heterozygous p.G146A
polymorphism on the other allele. This p.G146A is reported to have
approximately 80% of WT function and to be associated with
micropenis or cryptorchidism [WuQiang et al., 2003; Wada et al.,
2005, 2006]. Thus, we hypothesize that combination of the
hypomorphic polymorphism, together with the heterozygous frame-
shift mutation, reduces gene dosage of SF1 below haploinsufficiency,
resulting in the more severe phenotype observed in this patient.
While SF1 has a key role in testis development and function,
the effects of reduced SF1 activity in the ovary are less clear
[Hanley et al., 1999; Biason-Lauber and Schoenle, 2000]. The
identification of a heterozygous frameshift mutation in SF1 in the
mother of Patient 4 provides evidence that heterozygous SF1
mutations may be inherited in a sex-limited dominant fashion.
Mothers may carry such changes, but have preserved ovarian
function, whereas 46,XY offspring are affected. This finding has
important implications for counseling, as heterozygous females may
resemble ‘‘carriers’’ in an X-linked disorder.
Taken together, our findings show that heterozygous SF1
mutations are a relatively frequent finding in individuals with
46,XY DSD, and that the testis may be more sensitive to partial
loss of SF1 function than the adrenal gland in humans [Jameson,
FIGURE 2. DNA binding, expression, and cellular localization of
SF1. A: Electromobility shift assay showing wild-type (WT) and
mutant SF1 binding to a labeled probe corresponding to the
30 SF1 binding site of the Cyp11a promoter. In-vitro translated
empty vector (^) (lane 1) and an excess of unlabeled cold probe
(withWT SF1protein) (lane 7) wereused ascontrols. B:Cellular
localization of GFP-SF1 fusion proteins (green), generated and
expressed in tsa 201 cells using a pAcGFP-C1 vector. Nuclear
counterstaining was performed with DAPI (blue), and images
merged to con¢rm nuclear localization.WT SF1 showed strong
nuclear localization, with relative nucleolar exclusion and very
occasional nuclear subfoci. A similar expression and localiza-
tion pattern toWTwas seen for the p.R84H mutant. Clustering
in larger subnuclear foci was seen in the cells transfected with
thep.C33S mutant.Thep.Y138 Xmutantshoweddi¡usenuclear
localization.
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Human Mutation DOI 10.1002/humuFIGURE 3. A: E¡ect of the SF1mutants on transcriptional activity of theminimal promoters ofCyp11a in tsa 201cells as describedin
themethodssection. B: E¡ectoftheSF1mutantsonsynergisticactivationoftheLHbetapromoterbySF1andEgr1.C,D: E¡ectofthe
SF1 mutants on transcriptional activity of the Cyp11a and MIS promoter inTM3 (mouse Leydig) and TM4 (mouse Sertoli) cells,
respectively. E: Studies of a potential dominant negative e¡ect of mutant SF1were performed by transfectingincreasing amounts of
wild-type (WT) or mutant SF1 (p.C33S, p.R84H, p.Y138X) expressionvector (0,1,2,5,10ng) with1-ngempty vector (^) or1-ngWT
(1)a n daCyp11a promoterreporter (100ng) intsa 201cells. Additionalempty vectorwastransfectedtokeepDNA quantitiesconsis-
tent. Data represent themean7standarderrorof themean (SEM) of threeindependent experiments,eachperformedin triplicate.
TABLE 2. Molecular and Clinical Features of 46,XY IndividualsWith Mutations in SF1 (NR5A1)
Mutation Occurrence Inheritance
Adrenal
failure
External
genitalia
Testicular
dysgenesis
Mu º llerian
structures Reference
p.G35E Heterozygous De novo 1 Female Severe 1 Achermannet al.
[1999]
p.R92Q Homozygous Recessive 1 Female Not known 1 Achermannet al.
[2002]
c.424_427dupCCCA
1p.G146A
Heterozygous1
polymorphism
Not known   Female Severe 1 This report
p.M78I Heterozygous SLD   Female Mild (1) Linet al. [2007]
p.V15M Heterozygous De novo   Female Mild   Linet al. [2007]
p.C16X Heterozygous De novo   Ambiguous Mild 1 Malletet al.
[2004]
p.C91S Heterozygous SLD   Ambiguous Mild (1) Linet al. [2007]
c.18delC Heterozygous De novo   Ambiguous Mild   Hasegawa et al.
[2004]
c.1058_1065del
AGCTGGTG Heterozygous De novo   Ambiguous Regressed
a   Correaet al.
[2004]
p.C33S Heterozygous De novo   Ambiguous Mild   This report
p.R84H Heterozygous De novo   Ambiguous Normal   This report
p.Y138X Heterozygous De novo   Ambiguous Mild   This report
c.1277dup T Heterozygous SLD   Ambiguous Normal   This report
p.L437Q Heterozygous De novo   Hypospadias Mild   Linet al. [2007]
aGonadal tissue not found at laparoscopy at age 31years.
SLD, sex-limited dominant; 1,p r e s e n t ; , absent; (1), remnant present.
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adrenal insufficiency with time remains to be seen. Thus,
determining the genetic cause in 46,XY DSD can have
implications for investigation, counseling of families, and long-
term follow-up.
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